What Are Systemic Disease Causes of Oral Ulcers?
Discussion Oral ulcers are common problems seen by dentists but pediatricians also see them. Usually families have are concerned because they are painful and acute. Ulcers are sometime noticed by the physician and not the family as in the case of herpangina or hand-foot and mouth disease. Chronic or recurrent ulcerations present less commonly and therefore it may be more difficult to determine their etiology. Many of the systemic disease causes of oral ulcers are overall infrequent and/or not common in the pediatric age range. Ulcers can be classified in several ways but acute ulcers are usually painful and last less tha...
Source: PediatricEducation.org - September 21, 2020 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

NIH Launches Trial of Rigel Drug for Severe COVID-19 NIH Launches Trial of Rigel Drug for Severe COVID-19
The NIH on Thursday launched a clinical trial of fostamatinib, currently used to treat a blood platelet-destroying autoimmune disorder, in patients hospitalized with severe COVID-19.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - September 19, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Children who take steroids at increased risk for diabetes, high blood pressure, blood clots
(Rutgers University) Children who take oral steroids to treat asthma or autoimmune diseases have an increased risk of diabetes, high blood pressure, and blood clots, according to Rutgers researchers. The Rutgers study is the first to quantify these complications of oral steroids in a nationwide population of children. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 17, 2020 Category: International Medicine & Public Health Source Type: news

Companion Drug Might Help Prevent Kidney Complications of Lupus
WEDNESDAY, Sept. 16, 2020 -- Adding a newer drug to standard therapy might help control kidney complications caused by the autoimmune disease lupus, a new clinical trial suggests. The researchers found that adding the drug, called belimumab,... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 16, 2020 Category: General Medicine Source Type: news

New Graphic: Public-Private collaboration fuels the U.S. biopharmaceutical ecosystem
America ’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases, including cancer, rare diseases and autoimmune conditions. These advancements are due to the productivity of the United States ’biomedical R&D ecosystem, which is sustained by a policy framework that is designed to support and adva...
Source: The Catalyst - September 16, 2020 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Intellectual Property & D Focus Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Media News - September 10, 2020 Category: Pharmaceuticals Source Type: news

New data show Roche ’s ENSPRYNG (satralizumab) significantly reduces severity and risk of relapse in neuromyelitis optica spectrum disorder (NMOSD)
Basel, 10 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present new ENSPRYNG ® (satralizumab) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare disease of the central nervous system. These data are being presented at MSVirtual2020, the 8th joint ACTRIMS-ECTRIMS meeting, in addition to longer-term efficacy data supporting the continued effect of ENSPRYNG on reducing the risk of NMOSD relapse, as well as its favourable benefit:risk profile.“The data for ENSPRYNG at MSVirtual2020 are promising and suggest it significantly reduces relapse severity ...
Source: Roche Investor Update - September 10, 2020 Category: Pharmaceuticals Source Type: news

Pro-inflammatory lipids precede Type 1 diabetes onset in mouse model and children
(University of Alabama at Birmingham) Type 1 diabetes is an autoimmune disease where immune cells -- led by inflammatory macrophages -- attack and destroy the pancreatic beta cells. It now appears that inflammatory lipid signaling may help provoke this attack. Researchers have identified a proinflammatory lipid profile that precedes development of T1D in a mouse model and in children under age 15 who are at high risk for T1D. This finding may identify candidate lipid therapeutic targets to prevent T1D. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 9, 2020 Category: International Medicine & Public Health Source Type: news

Biopharma Leaders Unite To Stand With Science
NEW YORK, September 8, 2020 — The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and Canada, Moderna, Inc. (Nasdaq: MRNA), Novavax, Inc. (Nasdaq: NVAX), Pfizer Inc. (NYSE: PFE), and Sanofi (NASDAQ: SNY), today announced a historic pledge, outlining a united commitment to uphold the integrity of the scientific process as they work towards potential global regulatory filings and approvals of the first COVID-19 vaccines. All nine CEOs signed the following pledge: We, the un...
Source: Johnson and Johnson - September 8, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

NIDCR's Fall 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Fall 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastructu...
Source: NIDCR Science News - September 1, 2020 Category: Dentistry Source Type: news

Inova Diagnostics announces CE for Aptiva(R), a digital multi-analyte system
SAN DIEGO, Aug. 26, 2020 -- (Healthcare Sales & Marketing Network) -- Inova Diagnostics, a worldwide leader in IVD systems and reagents for autoimmune disease in the clinical laboratory, is pleased to announce CE (Conformité Européenne) Mark... Devices, Diagnostics, Regulatory Inova Diagnostics, Aptiva Celiac Disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2020 Category: Pharmaceuticals Source Type: news

Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
In an oversubscribed round, top-tier investors provide significant financial resources to accelerate clinical development of potentially best-in-class therapies for inflammatory/autoimmune diseases SAN DIEGO and TAICANG, SUZHOU, China, Aug. 24, 2020 -- ... Biopharmaceuticals, Venture Capital, Personnel Connect Biopharma, atopic dermatitis, ulcerative colitis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 24, 2020 Category: Pharmaceuticals Source Type: news

TNF Inhibitors Linked to Inflammatory CNS Events TNF Inhibitors Linked to Inflammatory CNS Events
Use of tumor necrosis factor inhibitors in patients with autoimmune diseases may increase risk for inflammatory demyelinating and non-demyelinating central nervous system events, new data suggest.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 22, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Johnson and Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen's Leadership in Novel Treatments for Autoimmune Diseases
$6.5 Billion Acquisition Through an All-Cash Tender Offer of $52.50 Per Momenta Share Lead Asset Nipocalimab Provides Opportunity for Janssen to Deliver Transformative Treatments in Autoantibody-Driven Autoimmune Diseases Momenta's Cambridge, Massach... Biopharmaceuticals, Mergers & Acquisitions Johnson & Johnson, Momenta Pharmaceuticals (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 19, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson to Acquire Momenta Pharmaceuticals, Inc., Expanding Janssen ’s Leadership in Novel Treatments for Autoimmune Diseases
NEW BRUNSWICK, N.J., August 19, 2020 – Johnson & Johnson (NYSE:JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. This acquisition provides an opportunity for the Janssen Pharmaceutical Companies of Johnson & Johnson to broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease. The transaction will include full global rights to nipocalim...
Source: Johnson and Johnson - August 19, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Coronavirus: Severe cases could trigger autoimmune disease
A case report from Garibaldi Hospital in Catania, Italy, tracked three coronavirus patients who were subsequently diagnosed with myasthenia gravis one week after fever onset. (Source: the Mail online | Health)
Source: the Mail online | Health - August 17, 2020 Category: Consumer Health News Source Type: news

FDA Approves Treatment for Rare Disease Affecting Optic Nerves, Spinal Cord
The FDA has approved a new treatment for neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody. NMOSD is a rare autoimmune disease that mainly affects the optic nerves and spinal cord. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Binding mechanisms of therapeutic antibodies to human CD20
Monoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differentiation 20) constitute important immunotherapies for the treatment of B cell malignancies and autoimmune diseases. Type I and II therapeutic mAbs differ in B cell binding properties and cytotoxic effects, reflecting differential interaction mechanisms with CD20. Here we present 3.7- to 4.7-angstrom cryo–electron microscopy structures of full-length CD20 in complexes with prototypical type I rituximab and ofatumumab and type II obinutuzumab. The structures and binding thermodynamics demonstrate that upon binding to CD20, type II mAbs form te...
Source: ScienceNOW - August 13, 2020 Category: Science Authors: Kumar, A., Planchais, C., Fronzes, R., Mouquet, H., Reyes, N. Tags: Biochemistry, Medicine, Diseases r-articles Source Type: news

GentiBio launches to develop engineered regulatory T cells for autoimmune and inflammatory diseases
(Verge Scientific Communications) GentiBio, Inc., an emerging biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases, announced today it has closed a $20 million seed funding led by OrbiMed, Novartis Venture Fund and RA Capital Management, L.P. GentiBio also announced it has entered into exclusive licensing partnerships with Seattle Children's Research Institute, Benaroya Research Institute at Virginia Mason (BRI), and MIGAL Galilee Research Institute (MIGAL) to advance the company's unique immune tolerance platform. (S...
Source: EurekAlert! - Medicine and Health - August 5, 2020 Category: International Medicine & Public Health Source Type: news

Identification of a new mechanism in the immune system provides knowledge about diseases
(Aarhus University) A recently identified mechanism in the immune system reveals a previously unknown protein that could provide an opening to a better understanding of infections and autoimmune diseases. This is shown by a new basic research study from Aarhus University, Denmark. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 4, 2020 Category: Infectious Diseases Source Type: news

Study: Enzyme could prove effective in treating tumors and inflammatory diseases in lung
(Henry Ford Health System) Findings from a research study led by scientists at Henry Ford suggest an enzyme could play an important role in the treatment of cancer and autoimmune diseases in the airway. Histone deacetylases (HDACs) are enzymes that help modulate gene expression by removing acetyl groups from histone or non-histone proteins. Inhibition of HDACs is emerging as a promising approach to treat various types of malignant diseases and inflammatory disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 4, 2020 Category: International Medicine & Public Health Source Type: news

Jefferson City Schools will be the first in Georgia to reopen Friday. These parents won't be sending their children
"They're going to open the floodgates wide open," said one mother who has an autoimmune disease. "And there's no way to (contact) trace. Once kids go from one class to the next class, to the next class, they cannot do the tracing." (Source: CNN.com - Health)
Source: CNN.com - Health - July 30, 2020 Category: Consumer Health News Source Type: news

His Face, Hands and Feet Swelled Up. What Was Going On?
The young boy ’s grandmother saw strange red lines snaking around his body. Could this be an allergic reaction? A rare autoimmune disease? (Source: NYT Health)
Source: NYT Health - July 30, 2020 Category: Consumer Health News Authors: Lisa Sanders, M.D. Tags: Children and Childhood Allergies Antibiotics Antihistamines Source Type: news

Your brain parasite isn't making you sick -- here's why
(University of Virginia Health System) The new discovery could have important implications for brain infections, neurodegenerative diseases and autoimmune disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 30, 2020 Category: International Medicine & Public Health Source Type: news

Hidradenitis Suppurativa is associated with childhood and lifetime traumatic events: a case control study - Gielen S, Janmohamed SR, Van Laethem A, Del Marmol V, Suppa M, Gutermuth J, Willemsen R.
BACKGROUND: Negative life events in childhood can increase the susceptibility to autoimmune and inflammatory diseases. Hidradenitis suppurativa (HS) is a systemic inflammatory disease affecting the apocrine sweat glands, characterized by abscesses, fistula... (Source: SafetyLit)
Source: SafetyLit - July 24, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

Dual role discovered for molecule involved in autoimmune eye disease
IL-17, known for driving inflammation, also puts on the brakes, NIH scientists report (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - July 23, 2020 Category: American Health Source Type: news

Viela Bio's journey to market with its first drug hasn't been without its bumps. But it's forging on.
The Gaithersburg biotech's drug is aimed at treating a life-threatening autoimmune disease called neuromyelitis optica spectrum disorder. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 23, 2020 Category: Biotechnology Authors: Sara Gilgore Source Type: news

GlycoNet invests $3.9 million to address research gaps in Canadian healthcare
(Canadian Glycomics Network) The Canadian Glycomics Network (GlycoNet) today awarded $3.9 million in grant funding to 11 collaborative research projects. The fund will support a wide range of multidisciplinary research teams across 17 Canadian research institutions and their industry partners to address unmet medical needs in cancer, gastrointestinal inflammations, cystic fibrosis, Sanfillipo disease, Parkinson's, and autoimmune diseases. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 23, 2020 Category: Cancer & Oncology Source Type: news

How the regulator is regulated -- Insight into immune-related protein holds therapeutic value
(Tokyo University of Science) Various proteins expressed in cells of the immune system have shown to play an important role in various disorders, including cancer, allergy, and autoimmune disease. In a new study, scientists find out how an immune checkpoint protein called PD-L2, which is expressed on the surface of a type of immune cells, is regulated at the molecular level. The findings of this study have the potential to usher in new developments in the field of immune therapy. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - July 21, 2020 Category: Biology Source Type: news

Scleroderma: your questions about the autoimmune disease answered
Yale Medicine ’s Dr. Monique Hinchcliff, director of the Yale Scleroderma Program, offers valuable information about the difficult-to-diagnose disorder. (Source: Yale Science and Health News)
Source: Yale Science and Health News - July 15, 2020 Category: Universities & Medical Training Source Type: news

What Causes Autoimmune Disease
? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - July 15, 2020 Category: General Medicine Source Type: news

R & D Focus: 5 things to know about the biopharmaceutical research ecosystem
America ’s biopharmaceutical companies are at the heart of a robust research and development (R&D) ecosystem that develops more innovative medicines than any other country in the world. In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases, including cancer, rare diseases and autoimmune conditions. These advancements are due to the productivity of the United States ’ biomedical research ecosystem, which is sustained by a policy framework that is designed to support and ad...
Source: The Catalyst - July 13, 2020 Category: Pharmaceuticals Authors: Jocelyn Ulrich Tags: Research and Development Intellectual Property & D Focus Coronavirus Source Type: news

Salmonella biofilm protein causes autoimmune responses -- Possible link with Alzheimer's
(University of Saskatchewan) Scientists from the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan (USask) and Temple University (Philadelphia, US) have demonstrated that a Salmonella biofilm protein can cause autoimmune responses and arthritis in animals. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 9, 2020 Category: International Medicine & Public Health Source Type: news

CHOP-pioneered spatial mapping method pinpoints potential new therapeutic targets in lupus
(Children's Hospital of Philadelphia) A team of researchers from Children's Hospital of Philadelphia (CHOP) used a new method of pinpointing potential disease-causing changes in the genome to identify two new potential therapeutic targets for lupus, while also paving the way for more accurately identifying disease-causing variations in other autoimmune disorders. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 8, 2020 Category: International Medicine & Public Health Source Type: news

Stanford biotech spinout snares $100M round on path toward IPO
Annexon Inc., a Stanford University spinout targeting a protein that could play a role in neurodegeneration and autoimmune and eye diseases, closed a $100 million round that may signal interest in an IPO. The South San Francisco company, led by President and CEO Ted Love, is looking to inhibit a pathway called complement. It has pushed two drugs into clinical trials and has raised more than $250 million. One drug, called ANX-005, is a monoclonal antibody in a Phase I/II study against Guillain-Barr é… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 3, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

LJI scientists investigate a powerful protein behind antibody development
(La Jolla Institute for Immunology) Scientists at the La Jolla Institute for Immunology (LJI) have discovered a potential new way to better fight a range of infectious diseases, cancers and even autoimmune diseases.The new study, published recently in Nature Immunology, shows how a protein works as a " master regulator " in the immune system. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 22, 2020 Category: Infectious Diseases Source Type: news

Hookworm trial offers new hope to MS patients
(University of Nottingham) Parasitic worms could offer a new treatment hope for patients suffering from the autoimmune disease multiple sclerosis, according to experts from the University of Nottingham. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 18, 2020 Category: Biology Source Type: news

Antibodies Tested as Possible COVID-19 Treatment Antibodies Tested as Possible COVID-19 Treatment
Giving patients antibodies to create passive immunity is an approach that's been used for decades to treat everything from cancer, to autoimmune diseases, to infections like RSV and HIV.WebMD Health News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - June 17, 2020 Category: Pathology Tags: Infectious Diseases News Source Type: news

Lupus Therapies Continue to Evolve
May is National Lupus Awareness Month, a good time to think about lupus and the challenges it presents to patients. Learn about this chronic, autoimmune disease and the promise of future therapies. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 17, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

The FDA Revoked Emergency Use Authorization for Hydroxychloroquine, Citing New Evidence
The U.S. Food and Drug Administration (FDA) announced today that it is revoking the emergency use authorization for hydroxychloroquine and chloroquine, citing a lack of evidence that these drugs are effective for COVID-19. Early on in the pandemic, doctors scrambling to find a way to treat the disease widely prescribed hydroxychloroquine to their sickest patients, based on thin evidence from a handful of relatively weak studies. However, recent research has made it increasingly clear that the drug is likely ineffective against the disease, and that it carries a risk of significant side effects, including heart problems. ...
Source: TIME: Health - June 15, 2020 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Source Type: news

The FDA Revokes Emergency Use Authorization for Hydroxychloroquine, Citing New Evidence
The U.S. Food and Drug Administration (FDA) announced today that it is revoking the emergency use authorization for hydroxychloroquine and chloroquine, citing a lack of evidence that these drugs are effective for COVID-19. Early on in the pandemic, doctors scrambling to find a way to treat the disease widely prescribed hydroxychloroquine to their sickest patients, based on thin evidence from a handful of relatively weak studies. However, recent research has made it increasingly clear that the drug is likely ineffective against the disease, and that it carries a risk of significant side effects, including heart problems. ...
Source: TIME: Health - June 15, 2020 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized COVID-19 Source Type: news

FDA Approves New Therapy for Rare Disease Affecting Optic Nerve, Spinal Cord
FDA approved Uplizna for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are positive for antibody called AQP4. NMOSD is a rare autoimmune disease that attacks the optic nerves and spinal cord. Uplizna is the second approved treatment for the disorder. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - June 11, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Bloating causes: When your stomach bloating could be a sign of an autoimmune disease
STOMACH BLOATING could be the result of a serious illness. An autoimmune disease could be attacking its own tissues. What could it be? (Source: Daily Express - Health)
Source: Daily Express - Health - June 11, 2020 Category: Consumer Health News Source Type: news

Cognitive Dysfunction in Autoimmune Rheumatic Diseases Cognitive Dysfunction in Autoimmune Rheumatic Diseases
A better understanding of the cognitive impacts in chronic autoimmune rheumatic diseases could have important implications for the screening and management of these patients.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 9, 2020 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Birmingham scientists 're-train' immune system to prevent attack of healthy cells
(University of Birmingham) The body's immune system can be re-wired to prevent it from recognising its own proteins which, when attacked by the body, can cause autoimmune diseases like multiple sclerosis, a significant new study by UK scientists has found. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 9, 2020 Category: International Medicine & Public Health Source Type: news

List of Currently Incurable Diseases
Listing of diseases considered to be incurable including disorders of both infectious and non-infectious, neoplastic, autoimmune, genetic, or metabolic that have no known current cure (Source: Disabled World)
Source: Disabled World - June 8, 2020 Category: Disability Tags: Disability and Health Lists Source Type: news

NIDCR's Summer 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page. NIDCR's Summer 2020 E-Newsletter In this issue: NIDCR News Funding Opportunities NIH/HHS News Funding Notices Science Advances Subscribe to NICDR News Grantee News   NIDCR News NIDCR Announces Availability of COVID-19 Research Funding On May 5, NIDCR issued two Notices of Special Interest highlighting the urgent need for research on coronavirus disease 2019. This research may be conducted either via the National Dental PBRN infrastruc...
Source: NIDCR Science News - June 4, 2020 Category: Dentistry Source Type: news

Understanding a gene's role in inflammatory bowel disease
(University of California - Riverside) A protein-coding gene associated with autoimmune diseases such as Crohn's disease and ulcerative colitis, collectively referred to as inflammatory bowel disease, or IBD, will be the focus of new research in the School of Medicine at the University of California, Riverside. The work is made possible by a National Institutes of Health grant exceeding $2.5 million. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2020 Category: International Medicine & Public Health Source Type: news

WHO Resumes Study of Hydroxychloroquine for Treating COVID-19
On June 3, the World Health Organization (WHO) resumed a study looking into whether the malaria drug hydroxychloroquine could be effective in treating COVID-19. Last week, the WHO temporarily stopped people from enrolling in the trial, part of a larger study called Solidarity that is investigating a number of different potential coronavirus therapies, over concerns about the hydroxychloroquine’s adverse effects on the heart. That followed the publication of a Lancet study on May 22, involving more than 96,000 people, which found that the drug did not improve survival among patients hospitalized with COVID-19, and tha...
Source: TIME: Health - June 4, 2020 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news

A G protein-biased S1P1 agonist, SAR247799, protects endothelial cells without affecting lymphocyte numbers
Endothelial dysfunction is a hallmark of tissue injury and is believed to initiate the development of vascular diseases. Sphingosine-1 phosphate receptor-1 (S1P1) plays fundamental physiological roles in endothelial function and lymphocyte homing. Currently available clinical molecules that target this receptor are desensitizing and are essentially S1P1 functional antagonists that cause lymphopenia. They are clinically beneficial in autoimmune diseases such as multiple sclerosis. In patients, several side effects of S1P1 desensitization have been attributed to endothelial damage, suggesting that drugs with the opposite eff...
Source: Signal Transduction Knowledge Environment - June 2, 2020 Category: Science Authors: Poirier, B., Briand, V., Kadereit, D., Schäfer, M., Wohlfart, P., Philippo, M.-C., Caillaud, D., Gouraud, L., Grailhe, P., Bidouard, J.-P., Trellu, M., Muslin, A. J., Janiak, P., Parkar, A. A. Tags: STKE Research Articles Source Type: news